Analysts’ Weekly Ratings Updates for Gamida Cell (GMDA)

Gamida Cell (NASDAQ: GMDA) has recently received a number of price target changes and ratings updates:

  • 11/26/2018 – Gamida Cell is now covered by analysts at Needham & Company LLC. They set a “buy” rating and a $23.00 price target on the stock.
  • 11/21/2018 – Gamida Cell is now covered by analysts at CIBC. They set an “outperform” rating and a $15.00 price target on the stock.
  • 11/21/2018 – Gamida Cell is now covered by analysts at Oppenheimer Holdings Inc.. They set an “outperform” rating and a $15.00 price target on the stock.
  • 11/21/2018 – Gamida Cell is now covered by analysts at BMO Capital Markets. They set a “buy” rating and a $19.00 price target on the stock.
  • 11/20/2018 – Gamida Cell is now covered by analysts at Royal Bank of Canada. They set an “outperform” rating and a $20.00 price target on the stock.

Shares of NASDAQ:GMDA opened at $13.54 on Friday. Gamida Cell Ltd has a 12-month low of $7.99 and a 12-month high of $15.39.

Gamida Cell Ltd., a clinical stage biopharmaceutical company, focuses on developing cell therapies to cure cancer, and rare and serious hematologic diseases in the United States, the European Union, and internationally. The company's lead product candidate is NiCord, a nicotinamide (NAM)-expanded cord blood cell therapy that is in Phase 3 clinical trials for use as a curative stem cell graft for patients in hematopoietic stem cell transplant.

Featured Story: What does EPS mean?

Receive News & Ratings for Gamida Cell Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell Ltd and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply